PL2430051T3 - Kompozycje zawierające przeciwciała do leczenia chorób związanych z komórkami B lub T CD5+ HLA-DR+ - Google Patents

Kompozycje zawierające przeciwciała do leczenia chorób związanych z komórkami B lub T CD5+ HLA-DR+

Info

Publication number
PL2430051T3
PL2430051T3 PL10720014T PL10720014T PL2430051T3 PL 2430051 T3 PL2430051 T3 PL 2430051T3 PL 10720014 T PL10720014 T PL 10720014T PL 10720014 T PL10720014 T PL 10720014T PL 2430051 T3 PL2430051 T3 PL 2430051T3
Authority
PL
Poland
Prior art keywords
hla
treating
compositions containing
related diseases
containing antibodies
Prior art date
Application number
PL10720014T
Other languages
English (en)
Inventor
Laurence Boumsell
Karine Lester
Séverine Loisel
Christian Berthou
Martine Cerruti
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Université De Bretagne Occidentale
Centre National De La Recherche Scientifique (Cnrs)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Université De Bretagne Occidentale, Centre National De La Recherche Scientifique (Cnrs) filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of PL2430051T3 publication Critical patent/PL2430051T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL10720014T 2009-05-14 2010-05-14 Kompozycje zawierające przeciwciała do leczenia chorób związanych z komórkami B lub T CD5+ HLA-DR+ PL2430051T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305434 2009-05-14
EP10720014.9A EP2430051B1 (en) 2009-05-14 2010-05-14 Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases

Publications (1)

Publication Number Publication Date
PL2430051T3 true PL2430051T3 (pl) 2017-04-28

Family

ID=41055306

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10720014T PL2430051T3 (pl) 2009-05-14 2010-05-14 Kompozycje zawierające przeciwciała do leczenia chorób związanych z komórkami B lub T CD5+ HLA-DR+

Country Status (7)

Country Link
US (1) US8679500B2 (pl)
EP (1) EP2430051B1 (pl)
DK (1) DK2430051T3 (pl)
ES (1) ES2584916T3 (pl)
PL (1) PL2430051T3 (pl)
PT (1) PT2430051T (pl)
WO (1) WO2010145895A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516046A (ja) 2011-05-26 2014-07-07 フンダシオ・クリニック・ペル・ア・ラ・レセルカ・ビオメディカ がん若しくは腫瘍の治療用の又はアジュバントとして使用される可溶性タンパク質ｃｄ５又はｃｄ６
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
US11369663B2 (en) 2016-06-07 2022-06-28 Washington University Detection of CD5 and methods and compositions for modulating CD5
CN119857155A (zh) 2017-11-29 2025-04-22 海德堡医药研究有限责任公司 用于耗尽cd5+细胞的组合物和方法
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
JP7578289B2 (ja) 2018-12-21 2024-11-06 マルチチュード インコーポレーテッド Ｍｕｃ１８に特異的な抗体
WO2020132190A1 (en) * 2018-12-21 2020-06-25 Multitude Inc. Antibodies specific to muc18
NZ781538A (en) 2019-04-24 2025-12-19 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
CA3140447A1 (en) * 2019-06-05 2020-12-10 Anthony Boitano T-cell depleting therapies
WO2021167952A2 (en) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
JP2023538108A (ja) * 2020-08-21 2023-09-06 シティ・オブ・ホープ 抗ｃｄ５抗体組成物及びその使用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN121712526A (zh) 2023-06-13 2026-03-20 辛瑟斯治疗股份有限公司 抗cd5抗体及其用途
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025120015A1 (en) * 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
FR3163070A1 (fr) 2024-06-07 2025-12-12 Centre National De La Recherche Scientifique NOUVEL ANTICORPS MONOCLONAL D’ISOTYPE IgM ANTI-HLA-DR POTENTIALISANT L’ACTIVITE D’ANTICORPS D’ISOTYPE IgG1 OU IgM ANTI-CD20

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10162870A1 (de) * 2001-12-20 2003-07-10 Alexander Cherkasky Fusionsproteinen gegen B-Zell-Tumoren
EP1479760A1 (de) * 2003-05-19 2004-11-24 ProBioGen AG Künstliches Immunorgan
ES2665422T3 (es) * 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados

Also Published As

Publication number Publication date
US20120121598A1 (en) 2012-05-17
ES2584916T3 (es) 2016-09-30
PT2430051T (pt) 2016-07-11
DK2430051T3 (en) 2016-07-04
EP2430051B1 (en) 2016-03-23
WO2010145895A1 (en) 2010-12-23
EP2430051A1 (en) 2012-03-21
US8679500B2 (en) 2014-03-25

Similar Documents

Publication Publication Date Title
PL2430051T3 (pl) Kompozycje zawierające przeciwciała do leczenia chorób związanych z komórkami B lub T CD5+ HLA-DR+
IL255009A0 (en) Preparations that cause the help of t cells
PL2475352T5 (pl) Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji
ZA201109364B (en) Stabilized protein compositions
ZA201203183B (en) Sulfomethylsuccinates, process for making same and compositions containing same
IL216061A0 (en) Compositions and methods for antibodies targeting complement protein c3b
GB0905863D0 (en) Novel composition
IL213990A0 (en) Compositions for decontamination
IL214664A (en) Compositions are useful for treating hair-related conditions
IL214374A0 (en) Process for purifying lipopeptides
EP2419446A4 (en) HUMANIZED ANTIBODY COMPOSITIONS AND METHOD FOR BINDING LYSOPHOSPHACIDIC ACID
IL219470A0 (en) Compositions containing fractalknie-binding proteins and uses thereof
GB0901966D0 (en) Composition
SG10201408508YA (en) Combination composition useful for treating cardiovascular diseases
IL216395A0 (en) Prothrombic complex composition
GB2476226B (en) Optimisation
GB0904941D0 (en) Composition
EP2421952A4 (en) COMPOSITIONS FOR THE TRANSFECTION OF BIOMOLECULES IN CELLS
GB0917736D0 (en) Gel composition
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
GB0904942D0 (en) Composition
PL2503883T3 (pl) Kompozycja dezynfekująca
GB0900582D0 (en) Tropical composition
GB0903688D0 (en) Composition
PL2263454T3 (pl) Kompozycja uzdatniająca